VTRS
Viatris Inc

3,778
Mkt Cap
$12.14B
Volume
5.27M
52W High
$13.55
52W Low
$6.85
PE Ratio
-3.58
VTRS Fundamentals
Price
$10.31
Prev Close
$10.41
Open
$10.39
50D MA
$10.17
Beta
0.77
Avg. Volume
11.3M
EPS (Annual)
-$0.5315
P/B
0.78
Rev/Employee
$459,678.13
Loading...
Loading...
News
all
press releases
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.
Zacks·7d ago
News Placeholder
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia in Japan and Certain Other Markets in the Asia-Pacific Region
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia in Japan and Certain Other Markets in the Asia-Pacific Region Viatris Completes...
PR Newswire·8d ago
News Placeholder
Viatris to Participate in Upcoming Investor Conferences
Viatris to Participate in Upcoming Investor Conferences Viatris to Participate in Upcoming Investor Conferences PR Newswire PITTSBURGH, Oct. 13, 2025 PITTSBURGH, Oct. 13, 2025 /PRNewswire/ -- Viatris...
PR Newswire·11d ago
News Placeholder
Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris
CEOs at Church & Dwight, Eli Lilly, and Viatris are buying shares after stock pullbacks, signaling insider confidence.
Zacks·2mo ago
News Placeholder
Insider Watch: 3 CEOs Buying the Dip
Large-cap stocks CHD, LLY, and VTRS have seen their respective CEOs make purchases over the last month. What do they see?
Zacks·2mo ago
News Placeholder
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates
VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.
Zacks·3mo ago
News Placeholder
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·3mo ago
News Placeholder
Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates
Viatris (VTRS) delivered earnings and revenue surprises of +10.71% and +2.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Zacks·3mo ago

Latest VTRS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.